Filtered By:
Cancer: Adenocarcinoma
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Cancers, Vol. 14, Pages 3162: Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo
In this study, siRNA was designed for the targeted knockdown of 15-bp deletion-type BRAF mRNA. This siRNA repressed the phosphorylation of extracellular-signal-regulated kinase proteins downstream of BRAF and suppressed cell growth in vitro and in vivo. Furthermore, siRNAs with 2′-O-methyl modifications at positions 2–5 reduce the seed-dependent off-target effects, as confirmed by reporter and microarray analyses. Thus, such siRNA is a promising candidate therapy for 15-bp deletion-type BRAF-induced tumorigenesis.
Source: Cancers - June 28, 2022 Category: Cancer & Oncology Authors: Jiaxuan Song Yoshiaki Kobayashi Yoshimasa Asano Atsushi Sato Hiroaki Taniguchi Kumiko Ui-Tei Tags: Article Source Type: research
